2024 International Conference of KWS with 4th Annual Meeting of ISHMB (2024.11)바로가기
페이지
pp.61-61
저자
Wenjing He, Md. Habibur Rahman, Johny Bajgai, Sofian Abdul-Nasir, Chaodeng Mo, Hui Ma, Goh Seong Hoon, Kim Bomi, Hyungdon Lee, Cheol-Su Kim, Kyu-Jae Lee
언어
영어(ENG)
URL
https://www.earticle.net/Article/A475545
원문정보
초록
영어
Airway inflammatory diseases like asthma is a global public health concern due to their chronic inflammatory effects on the respiratory mucosa. Recently, the application of molecular hydrogen (H₂) has been recognized for its antioxidant and anti-inflammatory properties. In this study, we investigated the therapeutic potential of H₂ in airway inflammation using an ovalbumin (OVA)-induced BALB/c mouse model of allergic asthma. Female BALB/c mice were sensitized and challenged with OVA to induce airway inflammation and thirty mice were randomly divided into five groups: NT (non-treatment), HTC (3% H₂ treatment only), NC (negative control, OVA only), PC (positive control, OVA + intranasal 1 mg/ml salbutamol 50μl), and HT (H₂ treatment, OVA + inhaled 3% H₂). Various inflammatory and oxidative stressinduced markers such as WBC and its differential counts, lung histology, reactive oxygen species (ROS), nitric oxide (NO), glutathione peroxidase (GPx), and catalase (CAT), cytokine levels such as interferongamma (IFN-γ), interleukin (IL)-4, tumor necrosis factor-alpha (TNF-α), (IL)-10, granulocyte-macrophage colony-stimulating factor (GM-CSF), (IL)-5, (IL)-13, and total immunoglobulin E (IgE) levels were investigated. Our results demonstrated that inhaled H₂ significantly reduced inflammatory cell infiltration, oxidative stress markers, and pro-inflammatory cytokines expression while upregulating antioxidant enzyme activity. Additionally, H₂ also significantly decreased serum IgE levels, a marker of allergic inflammation. Collectively, our findings suggest that H₂ inhalation could be a promising treatment option for airway inflammation, offering a novel approach with potential clinical applications.
Wenjing He [ Department of Convergence Medicine, Wonju College of Medicine, Yonsei University, Wonju 26426, Republic of Korea/Department of Global Medical Science, Wonju College of Medicine, Yonsei University, Wonju, Republic of Korea ]
Md. Habibur Rahman [ Department of Convergence Medicine, Wonju College of Medicine, Yonsei University, Wonju 26426, Republic of Korea ]
Johny Bajgai [ Department of Convergence Medicine, Wonju College of Medicine, Yonsei University, Wonju 26426, Republic of Korea ]
Sofian Abdul-Nasir [ Department of Convergence Medicine, Wonju College of Medicine, Yonsei University, Wonju 26426, Republic of Korea/Department of Global Medical Science, Wonju College of Medicine, Yonsei University, Wonju, Republic of Korea ]
Chaodeng Mo [ Department of Convergence Medicine, Wonju College of Medicine, Yonsei University, Wonju 26426, Republic of Korea/Department of Global Medical Science, Wonju College of Medicine, Yonsei University, Wonju, Republic of Korea ]
Hui Ma [ Department of Convergence Medicine, Wonju College of Medicine, Yonsei University, Wonju 26426, Republic of Korea/Department of Global Medical Science, Wonju College of Medicine, Yonsei University, Wonju, Republic of Korea ]
Goh Seong Hoon [ Department of Convergence Medicine, Wonju College of Medicine, Yonsei University, Wonju 26426, Republic of Korea ]
Kim Bomi [ Department of Convergence Medicine, Wonju College of Medicine, Yonsei University, Wonju 26426, Republic of Korea ]
Hyungdon Lee [ Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon Sacred Heart Hospital, Chuncheon 24253, Republic of Korea ]
Cheol-Su Kim [ Department of Convergence Medicine, Wonju College of Medicine, Yonsei University, Wonju 26426, Republic of Korea ]
Kyu-Jae Lee [ Department of Convergence Medicine, Wonju College of Medicine, Yonsei University, Wonju 26426, Republic of Korea/Department of Global Medical Science, Wonju College of Medicine, Yonsei University, Wonju, Republic of Korea ]